regulatory
confidence high
sentiment negative
materiality 0.82
Nasdaq to delist Lakewood-Amedex (LABT) after 30 days below $1.00; hearing sought
Lakewood-Amedex Biotherapeutics Inc.
- Nov 10, 2026 Nasdaq staff letter: closing bid price stayed below $1.00 for 30 consecutive business days, Sept 29 through Nov 9, 2026.
- Company is not eligible for a compliance cure period because it effected a 1-for-10 reverse stock split on June 22, 2026, within the prior year.
- Unless a hearing is requested by Nov 17, 2026, trading is suspended at the open on Nov 19, 2026 and Nasdaq files Form 25-NSE to delist.
- Company says it intends to timely request a Nasdaq Hearings Panel hearing, which would stay suspension, and may propose another reverse split.
- Company warns no assurance the Panel grants continued listing or that it regains compliance with Rule 5550(a)(2).
Featured in Daily 8-K Digest
Selected #5 for 2026-11-16.
Read digest